Management of Systemic Hypertension in Adults

Introduction to Hypertension Management

The American College of Cardiology and American Heart Association recommend treating all adults with hypertension to a blood pressure goal of <130/80 mmHg, with lifestyle modifications as foundational therapy and pharmacologic treatment initiated based on BP stage and cardiovascular risk 1, 2

The American College of Cardiology and American Heart Association define normal blood pressure as <120/80 mmHg, elevated blood pressure as 120-129/<80 mmHg, stage 1 hypertension as 130-139/80-89 mmHg, and stage 2 hypertension as ≥140/90 mmHg 1, 2, 3
The diagnosis of hypertension should be confirmed using out-of-office blood pressure measurements, such as home blood pressure monitoring or ambulatory blood pressure monitoring, to exclude white coat hypertension before initiating treatment 1, 4

The American Heart Association recommends implementing evidence-based lifestyle interventions for all patients with elevated blood pressure or hypertension, including sodium restriction to <1500 mg/day, potassium supplementation of 3500-5000 mg/day, weight loss, and physical activity of 90-150 minutes/week 1, 4
The DASH diet, which is rich in fruits, vegetables, whole grains, and low-fat dairy, can help reduce blood pressure by 8-14 mmHg 4

The American College of Cardiology and American Heart Association recommend initiating pharmacologic therapy in patients with stage 1 hypertension who have clinical cardiovascular disease, a 10-year ASCVD risk ≥10%, diabetes mellitus, or chronic kidney disease, and in all patients with stage 2 hypertension 1, 2, 5
Thiazide diuretics, calcium channel blockers, ACE inhibitors, and angiotensin receptor blockers are recommended as first-line antihypertensive medications 1, 2, 5

The American College of Cardiology and American Heart Association recommend treating patients with chronic kidney disease and hypertension to a blood pressure goal of <130/80 mmHg, using an ACE inhibitor or angiotensin receptor blocker as first-line therapy 2, 6, 7
In patients with diabetes mellitus, antihypertensive drug therapy should be initiated at a blood pressure of ≥130/80 mmHg, with a treatment goal of <130/80 mmHg 2, 8
Older adults (≥65 years) should be treated to the same blood pressure target as younger patients, provided treatment is well tolerated 8, 7

The target blood pressure for all adults with hypertension after initiating drug therapy is <130/80 mmHg, regardless of ASCVD risk 1, 2, 5, 9

The follow-up schedule for patients with hypertension should be based on blood pressure category, with normal blood pressure (<120/80 mmHg) checked annually, elevated blood pressure (120-129/<80 mmHg) checked every 3-6 months, and stage 1 hypertension not qualifying for drug therapy checked every 3-6 months 3, 4
Patients initiating drug therapy should be followed approximately monthly for drug titration until blood pressure is controlled 1, 5

Stage 1 hypertension (130‑139 mm Hg / 80‑89 mm Hg) – initiate antihypertensive medication in adults who have established cardiovascular disease, a 10‑year ASCVD risk ≥ 10 %, diabetes mellitus, or chronic kidney disease. European Society of Cardiology (ESC) guideline 10
Stage 2 hypertension (≥140 mm Hg / ≥90 mm Hg) – initiate antihypertensive medication in all adults regardless of cardiovascular risk profile. ESC guideline 10
Target blood pressure after therapy initiation – aim for a systolic/diastolic pressure < 130/80 mm Hg in all treated adults. American College of Cardiology/American Heart Association (ACC/AHA) guideline 11

Diabetes mellitus – start pharmacologic therapy when blood pressure reaches ≥ 130/80 mm Hg after a maximum of three months of lifestyle modification; if tolerated, target systolic pressure 120‑129 mm Hg. ESC guideline 12
Chronic kidney disease (moderate‑to‑severe) – begin treatment at ≥ 130/80 mm Hg; if estimated GFR > 30 mL/min/1.73 m² and tolerated, aim for systolic pressure 120‑129 mm Hg. ESC guideline 12
Atherosclerotic disease (history of stroke or TIA) – initiate therapy at ≥ 130/80 mm Hg; target systolic pressure 120‑129 mm Hg to reduce subsequent cardiovascular events. ESC guideline 12

Routine initiation – nifedipine (any formulation) should not be used as first‑line therapy for routine hypertension management.
Add‑on therapy – extended‑release nifedipine may be added when blood pressure remains ≥ 130/80 mm Hg despite maximized first‑line agents (ACE inhibitor/ARB or thiazide diuretic). ESC guideline 12
Pregnancy – extended‑release nifedipine is recommended as a first‑line agent for pregnant women with chronic or gestational hypertension when blood pressure is ≥ 140/90 mm Hg. ESC guideline 12

Short‑acting nifedipine is contraindicated for hypertensive emergencies or urgencies because rapid BP drops can precipitate renal, cerebral, or coronary ischemia. American Heart Association (AHA) guideline 13
Hypertensive emergencies – defined by BP ≥ 180/120 mm Hg with progressive target‑organ dysfunction; require intravenous antihypertensives in an ICU setting, not oral nifedipine. AHA guideline 13
Hypertensive urgencies – severe BP elevation without progressive organ dysfunction; management should involve gradual BP reduction over 24‑48 h with appropriate oral agents, avoiding short‑acting nifedipine. AHA guideline 13

Do not use short‑acting nifedipine for acute BP lowering in any clinical scenario. AHA guideline 13
Avoid nifedipine monotherapy for newly diagnosed hypertension; preferred first‑line agents are thiazide diuretics, ACE inhibitors, ARBs, or long‑acting calcium‑channel blockers. American Heart Association (AHA) guideline 14